TLX101-CDx Given Complete Response Letter for Glioma Imaging
The FDA granted a complete response letter with no safety concerns for the new drug application for TLX101-CDx’s use in glioma imaging.
Related Articles
NCCN Guidelines Now Recommend Naxitamab for High-Risk Neuroblastoma
An update to the NCCN guidelines recommends naxtiamab-gqgk for adult and pediatric patients with high-risk neuroblastoma.
Avutometinib/Defactinib Earns FDA Accelerated Approval for KRAS+ LGSOC
The FDA has granted accelerated approval to avutometinib and defactinib in KRAS-mutated recurrent low-grade serious ovarian cancer.
Racial, Ethnic Disparities Present in Pediatric Brain Cancer Survival
Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.
RX Road Map: Daratumumab and Hyaluronidase-fihj
A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.
Eftilagimod Alfa/Pembrolizumab May Improve OS in HNSCC With CPS < 1
New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.
Lurbinectedin Plus Pembrolizumab May Yield Activity in Relapsed SCLC
Early-phase LUPER trial results suggest the lurbinectedin/pembrolizumab combination may benefit patients with relapsed small cell lung cancer.
Clinical Trials Can Open Doors for Patients With Myeloproliferative Neoplasms
Clinical trials can provide patients with myeloproliferative neoplasms expanded treatment options.
Daratumumab Combo Maintains Benefit in Transplant-Ineligible NDMM
Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.
A Snapshot of April FDA Approvals in Oncology for Nurses and APPs
Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.
Cretostimogene Grenadenorepvec Yields Durable Response in NMIBC
Cretostimogene grenadenorepvec showed complete response across subgroups in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.